Outcomes
|
OR (95 % CI)
|
---|
Base casea
|
Using fixed-effects model
|
RCTs includeda
|
Non-randomized cohort studies includeda
|
---|
TIVAD-related infections
|
0.71 (0.48–1.04)
|
0.70 (0.47–1.03)
|
0.47 (0.17–1.28)
|
0.76 (0.50–1.16)
|
Catheter-related thrombotic complications
|
0.76 (0.38–1.51)
|
0.91 (0.57–1.43)
|
0.90 (0.17–4.68)
|
0.56 (0.27–1.16)
|
Total major mechanical complications
|
0.38 (0.24–0.61)
|
0.36 (0.26–0.49)
|
0.30 (0.17–0.53)
|
0.44 (0.22–0.88)
|
Catheter dislocation
|
0.43 (0.22–0.84)
|
0.43 (0.23–0.83)
|
NAb
|
0.40 (0.15–1.07)
|
Malfunction
|
0.42 (0.28–0.62)
|
0.42 (0.28–0.62)
|
0.28 (0.12–0.64)
|
0.47 (0.30–0.74)
|
Catheter fracture
|
0.47 (0.21–1.05)
|
0.38 (0.18–0.78)
|
NAb
|
0.50 (0.15–1.61)
|
- Abbreviation: NA not applicable
- aRandom-effects model was used in these analyses
- bSensitivity analysis was not conducted because only one study was included